| ObjectiveThe expression of Chk1 and c-Myc in breast cancer tissues before and after neoadjuvant chemotherapy was measured,and the relationship with the general clinicopathological features of the patients was analyzed.To analyze the correlation between Chk1 and c-Myc expression in cancer tissues before and after neoadjuvant chemotherapy for breast cancer.To explore the relationship between the expression of Chk1 and c-Myc in breast cancer tissues before and after neoadjuvant chemotherapy and the prognosis of breast cancer,in order to find the biological indicators to predict the effect and prognosis of neoadjuvant chemotherapy.MethodsImmunohistochemical staining of Chk1 and c-Myc was performed on the paraffin sections of cancer tissue of before and after surgery of 115 patients who were included in the experimental criteria and observed the expression of Chk1 and c-Myc.IBM SPSS Statistics24 software was used to analyze the relationship between Chk1 and c-Myc versus various clinicopathological characteristics of patients.Analyzing the relationship between the molecular subtypes of breast cancer and tumor infiltrating lymphocytes versus the expression of Chk1 and c-Myc before and after neoadjuvant chemotherapy.To analyze the relationship between the expression levels of Chk1 and c-Myc versus MP grade before chemotherapy.Analyzing the correlation between Chk1 and c-Myc.Kaplan-Meier survival curve method(Log-rank test)was used to analyze the expression of Chk1 and c-Myc before and after chemotherapy versus relationship of OS and PFS of patients in three years and five years.Results1.The positive rates of Chk1 and c-Myc expression in breast cancer tissues before neoadjuvant chemotherapy were 73% and 74.8%,and the positive rates after chemotherapy were 70.9% and 50.0%.2.The expression of Chk1 in breast cancer tissues before neoadjuvant chemotherapy was significantly different from the age of patients,clinical stage of tumor and the expression of p53(P<0.05).There was no significant difference between them in menstrual status,lymphnode metastasis,tumor T stage,ER,PR,C-erbB-2,ki-67,TIL and other clinicopathological features(P>0.05).The expression of Chk1 in breast cancer tissues after neoadjuvant chemotherapy was significantly different from the expression of PR and Ki-67(P<0.05).There was no significant difference in age,menstrual status,lymph node metastasis,tumor T stage,clinical stage,ER,C-erbB-2,p53 and other clinicopathological features(P>0.05).The changes in expression of Chk1 before and after neoadjuvant chemotherapy were statistically significant(P<0.05).3.Expression of c-Myc in breast cancer tissues before neoadjuvant chemotherapy was not statistically significant with age,menstrual status,lymph node metastasis,tumor T stage,clinical stage,ER,PR,C-erbB-2,Ki-67,p53 and TIL(P>0.05).The expression of c-Myc in breast cancer tissues after neoadjuvant chemotherapy was significantly different from the expression of age,menstrual status,clinical stage and Ki-67 in patients(P<0.05),There was no significant difference in lymph node metastasis,tumor T stage,ER,PR,C-erbB-2 and p53(P>0.05).The changes in expression of c-Myc before and after neoadjuvant chemotherapy were statistically significant(P<0.05).4.There was no correlation between the expression of Chk1 and c-Myc before and after neoadjuvant chemotherapy(P>0.05).5.Before neoadjuvant chemotherapy,Molecular typing of breast cancer and TIL versus MP grades were statistically significant(P<0.05).Triple negative breast cancer had the highest PCR rate after neoadjuvant chemotherapy,followed by Luminal B breast cancer.Patients with a high proportion of TIL had the highest proportion of PCR after chemotherapy,followed by medium and low proportions.6.The expressions of Chk1 and c-Myc before and after neoadjuvant chemotherapy were not significantly different in breast cancer molecular typing,MP grading,bone marrow suppression,chemotherapy cycle,chemotherapy regimens and TIL(P>0.05).7.The expression of Chk1 before neoadjuvant chemotherapy was correlated with patients’ 5-year OS(P<0.05).The expression of Chk1 after neoadjuvant chemotherapy was correlated with patients’ 5-year PFS and OS(P<0.05).Before and after neoadjuvant chemotherapy,the expression of c-Myc was not correlated with patients’ 3-year,5-year OSand PFS(P>0.05).8.Kaplan-Meier survival curve method was used to analyze the expression of Chk1 and c-Myc before and after chemotherapy,Log-rank test.The results showed that the 5-year OS of patients with negative and weak positive Chk1 expression in breast cancer tissues before chemotherapy was significantly higher than the expression of Chk1 with midpositive and strong positive,with statistical significance(P<0.05).After chemotherapy,the 5-year PFS and OS of patients with negative Chk1 expression in breast cancer tissues were significantly higher than the expression of positive Chk1,with statistical significance(P<0.05).The expression of c-Myc before and after neoadjuvant chemotherapy was not correlated with patients’ 3-year,5-year OS and PFS(P>0.05).Conclusion1.There was a significant difference in the expression of Chk1 before and after neoadjuvant chemotherapy for breast cancer.Neoadjuvant chemotherapy can enhance the expression of Chk1.The expression of Chk1 in breast cancer tissues was negatively correlated with the prognosis of patients.Patients with negative expression could obtain longer PFS and OS,indicating that Chk1 is expected to be an indicator for predicting the prognosis of breast cancer.2.The expression of c-Myc was significantly different in before and after neoadjuvant chemotherapy for breast cancer.Neoadjuvant chemotherapy significantly decreased the expression of c-Myc in breast cancer tissues,but the expression of c-Myc was not associated with prognosis.3.The expression of Chk1 and c-Myc before and after neoadjuvant chemotherapy for breast cancer was not correlated. |
PDF Full Text Request